On June 10, 2021, Lumosa Therapeutics Co., Ltd. Board approved the amendments of an Exclusive Licensing Agreement on the long-acting analgesic injection for animal with Skyline Vet Pharma (SVP), and the worldwide right was granted to SVP. To accelerate the process of building a global market presence for the veterinary analgesic and realizing licensing revenue, the amended agreement allowed SVP to be responsible for the global supply of the veterinary analgesic, so the upfront and milestone payment are decreased to USD 900,000 from USD 1,000,000, and sharing from SVP sublicensing revenue and royalties revenue are adjusted. Taiwan Ministry of Science and Technology and National Defense Medical Center licensed the exclusive development and commercialization rights and relevant technologies of LT1001 to Lumosa.

In turn, Lumosa shall pay 20% of considerations from sublicense fee to the licensor.